Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)
Canadian Journal of Health Technologies · 12.03.2026 · 6 (3)
DOI: 10.51731/cjht.2026.1378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 12.03.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)Oral tablets:Vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mgVanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Zitieren
APA
CDA-AMC (2026). Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1378
Vancouver
CDA-AMC. Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1378
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {3},
doi = {10.51731/cjht.2026.1378}
}
EUVIMED